Subjects -> MEDICAL SCIENCES (Total: 8186 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (205 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (19 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (227 journals)
    - DENTISTRY (266 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (178 journals)
    - GERONTOLOGY AND GERIATRICS (125 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (178 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (90 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2230 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (135 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (150 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (153 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (182 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (151 journals)

HEMATOLOGY (160 journals)                     

Showing 1 - 122 of 122 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 3)
Adipocyte     Open Access  
Advances in Hematology     Open Access   (Followers: 13)
Africa Sanguine     Full-text available via subscription  
American Journal of Hematology     Hybrid Journal   (Followers: 46)
Anemia     Open Access   (Followers: 6)
Annals of Hematology     Hybrid Journal   (Followers: 14)
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 25)
Artery Research     Hybrid Journal   (Followers: 4)
Artificial Cells, Nanomedicine and Biotechnology     Hybrid Journal   (Followers: 3)
ASAIO Journal     Hybrid Journal   (Followers: 2)
Best Practice & Research Clinical Haematology     Hybrid Journal   (Followers: 5)
Blood     Hybrid Journal   (Followers: 296)
Blood Advances     Open Access   (Followers: 9)
Blood and Lymphatic Cancer : Targets and Therapy     Open Access   (Followers: 7)
Blood Cancer Journal     Open Access   (Followers: 21)
Blood Cells, Molecules, and Diseases     Hybrid Journal   (Followers: 5)
Blood Coagulation & Fibrinolysis     Hybrid Journal   (Followers: 27)
Blood Pressure     Open Access   (Followers: 1)
Blood Pressure Monitoring     Hybrid Journal   (Followers: 2)
Blood Reviews     Hybrid Journal   (Followers: 20)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 23)
Bone Marrow Transplantation     Hybrid Journal   (Followers: 15)
British Journal of Haematology     Hybrid Journal   (Followers: 54)
Canadian Journal of Diabetes     Hybrid Journal   (Followers: 9)
Case Reports in Hematology     Open Access   (Followers: 10)
Clinical and Applied Thrombosis/Hemostasis     Open Access   (Followers: 28)
Clinical Diabetes     Full-text available via subscription   (Followers: 30)
Clinical Diabetes and Endocrinology     Open Access   (Followers: 14)
Clinical Lymphoma & Myeloma     Full-text available via subscription   (Followers: 2)
Conquest : The Official Journal of Diabetes Australia     Full-text available via subscription   (Followers: 1)
Current Angiogenesis     Hybrid Journal   (Followers: 1)
Current Diabetes Reports     Hybrid Journal   (Followers: 14)
Current Diabetes Reviews     Hybrid Journal   (Followers: 13)
Current Hematologic Malignancy Reports     Hybrid Journal   (Followers: 2)
Current Opinion in Hematology     Hybrid Journal   (Followers: 14)
Cytotherapy     Full-text available via subscription   (Followers: 1)
Der Diabetologe     Hybrid Journal  
Diabetes     Full-text available via subscription   (Followers: 262)
Diabetes aktuell     Hybrid Journal   (Followers: 2)
Diabetes and Vascular Disease Research     Hybrid Journal   (Followers: 8)
Diabetes Care     Full-text available via subscription   (Followers: 285)
Diabetes Case Reports     Open Access  
Diabetes Educator     Hybrid Journal   (Followers: 10)
Diabetes Research and Clinical Practice     Hybrid Journal   (Followers: 18)
Diabetes Spectrum     Full-text available via subscription   (Followers: 14)
Diabetes Technology & Therapeutics     Hybrid Journal   (Followers: 8)
Diabetes Therapy     Open Access   (Followers: 13)
Diabetic Foot & Ankle     Open Access   (Followers: 9)
Diabetic Medicine     Hybrid Journal   (Followers: 93)
Diabetologia     Hybrid Journal   (Followers: 107)
Diabetologie und Stoffwechsel     Hybrid Journal  
Egyptian Journal of Hematology and Bone Marrow Transplantation     Open Access   (Followers: 9)
eJHaem     Open Access   (Followers: 1)
European Journal of Haematology     Hybrid Journal   (Followers: 12)
Experimental Hematology     Hybrid Journal   (Followers: 3)
Experimental Hematology & Oncology     Open Access   (Followers: 6)
Expert Review of Hematology     Hybrid Journal   (Followers: 4)
Fluids and Barriers of the CNS     Open Access   (Followers: 1)
Haematologica - the Hematology journal     Open Access   (Followers: 35)
Haemophilia     Hybrid Journal   (Followers: 15)
Hematologia     Full-text available via subscription   (Followers: 3)
Hematology     Open Access   (Followers: 9)
Hematology, Transfusion and Cell Therapy     Open Access   (Followers: 2)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 3)
Immunohematology : Journal of Blood Group Serology and Molecular Genetics     Hybrid Journal   (Followers: 3)
Indian Journal of Hematology and Blood Transfusion     Hybrid Journal   (Followers: 1)
Info Diabetologie     Full-text available via subscription  
InFo Hämatologie + Onkologie : Interdisziplinäre Fortbildung von Ärzten für Ärzte     Full-text available via subscription  
Integrated Blood Pressure Control     Open Access   (Followers: 1)
International Blood Research & Reviews     Open Access  
International Journal of Clinical Transfusion Medicine     Open Access   (Followers: 3)
International Journal of Diabetes in Developing Countries     Hybrid Journal   (Followers: 5)
International Journal of Diabetes Research     Open Access   (Followers: 6)
International Journal of Hematology     Hybrid Journal   (Followers: 3)
International Journal of Hematology Research     Open Access   (Followers: 2)
International Journal of Laboratory Hematology     Hybrid Journal   (Followers: 24)
JMIR Diabetes     Open Access  
Journal of Blood Medicine     Open Access  
Journal of Cerebral Blood Flow & Metabolism     Hybrid Journal   (Followers: 3)
Journal of Diabetes     Open Access   (Followers: 12)
Journal of Diabetes and its Complications     Hybrid Journal   (Followers: 13)
Journal of Diabetes and Metabolic Disorders     Open Access   (Followers: 6)
Journal of Diabetes Investigation     Open Access   (Followers: 6)
Journal of Diabetes Mellitus     Open Access   (Followers: 4)
Journal of Hematological Malignancies     Open Access  
Journal of Hematology and Transfusion Medicine     Open Access   (Followers: 1)
Journal of Hematopathology     Hybrid Journal   (Followers: 3)
Journal of Pediatric Hematology/Oncology     Hybrid Journal   (Followers: 6)
Journal of Social Health and Diabetes     Open Access  
Journal of Thrombosis and Haemostasis     Hybrid Journal   (Followers: 52)
Journal of Thrombosis and Thrombolysis     Hybrid Journal   (Followers: 30)
Leukemia     Hybrid Journal   (Followers: 23)
Leukemia and Lymphoma     Hybrid Journal   (Followers: 13)
Leukemia Research     Hybrid Journal   (Followers: 9)
Leukemia Research Reports     Open Access   (Followers: 1)
Leukemia Supplements     Full-text available via subscription  
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Nutrition & Diabetes     Open Access   (Followers: 18)
Oncohematology     Open Access   (Followers: 1)
Open Diabetes Journal     Open Access  
Open Hematology Journal     Open Access   (Followers: 1)
Open Hypertension Journal     Open Access  
Open Journal of Blood Diseases     Open Access  
Pediatric Blood & Cancer     Hybrid Journal   (Followers: 6)
Pediatric Hematology Oncology Journal     Open Access   (Followers: 3)
Peritoneal Dialysis International     Hybrid Journal  
Plasmatology     Open Access   (Followers: 1)
Platelets     Hybrid Journal   (Followers: 2)
Practical Diabetes     Hybrid Journal   (Followers: 4)
Primary Care Diabetes     Hybrid Journal   (Followers: 16)
Research and Practice in Thrombosis and Haemostasis     Open Access   (Followers: 2)
Revista Cubana de Hematología, Inmunología y Hemoterapia     Open Access  
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Seminars in Thrombosis and Hemostasis     Hybrid Journal   (Followers: 28)
The Lancet Haematology     Full-text available via subscription   (Followers: 43)
Therapeutic Advances in Hematology     Hybrid Journal  
Thrombosis & Haemostasis     Hybrid Journal   (Followers: 105)
Thrombosis Research     Hybrid Journal   (Followers: 30)
Transplantation and Cellular Therapy     Hybrid Journal   (Followers: 11)
Veins and Lymphatics     Open Access   (Followers: 1)

           

Similar Journals
Journal Cover
Haematologica - the Hematology journal
Journal Prestige (SJR): 3.063
Citation Impact (citeScore): 4
Number of Followers: 35  

  This is an Open Access Journal Open Access journal
ISSN (Print) 0390-6078 - ISSN (Online) 1592-8721
Published by Ferrata Storti Foundation Homepage  [1 journal]
  • Immunosuppression with post-transplant cyclophosphamide for allogeneic
           hematopoietic cell transplantation

    • Authors: Mary Eapen
      PubDate: Mon, 01 Jul 2024 00:00:00 +000
       
  • Erratum to: Ultra-deep mutational landscape in chronic lymphocytic
           leukemia uncovers dynamics of resistance to targeted therapies

    • Authors: David W. Woolston; Nathan D. Lee, Mazyar Shadman, Elena Latorre-Esteves, Xin Ray Tee, Jeanne Fredrickson, Brendan F. Kohrn, Chaitra Ujjani, Ashley Eckel, Brian Till, Min Fang, Jerald Radich, Ivana Bozic, Rosa Ana Risques, Cecilia C.S. Yeung
      PubDate: Mon, 01 Jul 2024 00:00:00 +000
       
  • Erratum to: Genomic breakpoint-specific monitoring of measurable residual
           disease in pediatric non-standard risk acute myeloid leukemia

    • Authors: Margarita Maurer-Granofszky; Stefan Köhrer, Susanna Fischer, Angela Schumich, Karin Nebral, Patrizia Larghero, Claus Meyer, Astrid Mecklenbräuker, Nora Mühlegger, Rolf Marschalek, Oskar A. Haas, Renate Panzer-Grümayer, Michael N. Dworzak
      PubDate: Mon, 01 Jul 2024 00:00:00 +000
       
  • High annualized bleeding rates in pediatric patients with inherited
           platelet function disorders

    • Authors: Shelly Saini; Song Zhang, Sean Yates, Jessica Garcia, Ruchika Sharma, Joseph Formella, Ravindra Sarode, Ayesha Zia
      PubDate: Thu, 28 Mar 2024 00:00:00 +000
       
  • Efficacy and safety of daratumumab plus bortezomib and dexamethasone in
           newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a
           prospective phase II study

    • Authors: Kai-ni Shen; Ya-juan Gao, Long Chang, Lu Zhang, Xin-xin Cao, Zhuang Tian, Yi-ning Wang, Dao-bin Zhou, Jian Li
      PubDate: Thu, 28 Mar 2024 00:00:00 +000
       
  • Elderly long-term survivors in the Nordic phase II study with first-line
           maintenance temozolomide for primary central nervous system lymphoma: a
           10-year follow-up

    • Authors: Elisa Jacobsen Pulczynski; Mikkel Runason Simonsen, Outi Kuittinen, Unn-Merete Fagerli, Martin Erlanson, Øystein Fluge, Sirpa Leppä, Bjørn Østenstad, Alexander Fosså, Mikael Eriksson, Tarec El-Galaly, Hanne Kuitunen, Karin Papworth, Maria Ljungqvist, Martin B. Pedersen, Marjukka Pollari
      PubDate: Thu, 28 Mar 2024 00:00:00 +000
       
  • Type I interferons: leukemia's old foe in the limelight again

    • Authors: Anil Kumar; Srividya Swaminathan
      PubDate: Thu, 21 Mar 2024 00:00:00 +000
       
  • Bendamustine and rituximab as first-line treatment for symptomatic splenic
           marginal zone lymphoma: long-term outcome and impact of early unmeasurable
           minimal residual disease attainment from the BRISMA/IELSG36 phase II study
           

    • Authors: Emilio Iannitto; Simone Ferrero, Côme Bommier, Daniela Drandi, Martina Ferrante, Krimo Bouabdallah, Sylvain Carras, Guido Gini, Vincent Camus, Salvatrice Mancuso, Luigi Marcheselli, Angela Ferrari, Michele Merli, Benoit Tessoulin, Caterina Stelitano, Kheira Beldjord, Giovanni Roti, Fabrice Jardin, Barbara Castagnari, Francesca Palombi, Lucile Baseggio, Alexandra Traverse-Glehen, Claudio Tripodo, Anna Marina Liberati, Margherita Parolini, Sara Usai, Caterina Patti, Massimo Federico, Maurizio Musso, Marco Ladetto, Emanuele Zucca, Catherine Thieblemont
      PubDate: Thu, 14 Mar 2024 00:00:00 +000
       
  • Validation of LymphGen classification on a 400-gene clinical
           next-generation sequencing panel in diffuse large B-cell lymphoma:
           real-world experience from a cancer center

    • Authors: Meng-Lei Zhu; Esther Drill, Erel Joffe, Gilles Salles, Alfredo Rivas Delgado, Andrew Zelenetz, Maria Lia Palomba, Maria Arcila, Ahmet Dogan
      PubDate: Thu, 14 Mar 2024 00:00:00 +000
       
  • Hematopoietic stem cell fate under the influence of Ser/Thr protein
           phosphatases

    • Authors: Meritxell Alberich-Jorda; Libor Macurek
      PubDate: Thu, 07 Mar 2024 00:00:00 +000
       
  • High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell
           malignancies

    • Authors: Othman Al-Sawaf
      PubDate: Thu, 07 Mar 2024 00:00:00 +000
       
  • Incidence and outcome of central nervous system relapse after
           hematopoietic stem cell transplantation in patients suffering from acute
           myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute
           Leukemia Working Party of the European Society for Blood and Marrow
           Transplantation

    • Authors: Sabine Blum; Yves Chalandon, Myriam Labopin, Jürgen Finke, Tobias Gedde-Dahl, Tarek Ben Othman, Jan J. Cornelissen, Pavel Jindra, Hélène Labussière-Wallet, Matthew Collin, Stig Lenhoff, Guido Kobbe, Norma C. Gutiérrez, Arnon Nagler, Mohamad Mohty
      PubDate: Thu, 07 Mar 2024 00:00:00 +000
       
  • Hemostasis and endothelial functionality: the double face of coagulation
           factors

    • Authors: Cristina Olgasi; Simone Assanelli, Alessia Cucci, Antonia Follenzi
      Abstract: Hemostasis is a sophisticated sequence of events aimed at repairing vessel injury. This process occurs in combination with angiogenesis, which leads to new blood vessel formation, helping in wound repair and facilitating tissue healing. The fine mechanisms that regulate hemostasis and angiogenesis are well described, but for a long time, coagulation factors (CF) have been considered merely players in the coagulation cascade. However, evidence from several experiments highlights the crucial functions of these CF in regulating endothelial functionality, especially in the angiogenic process. Some of these CF (e.g., thrombin and tissue factor) have been widely investigated and have been described as triggering intracellular signaling related to endothelial cell (EC) functionality. For others (e.g., factor VIII and thrombomodulin), potential receptors and molecular mechanisms have not been fully elucidated but some data show their potential to induce EC response. This review focuses on the emerging roles of selected CF in regulating EC functions, highlighting in particular their ability to activate signaling pathways involved in angiogenesis, migration, proliferation and endothelial barrier stability.
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis

    • Authors: Gael Vermeersch; Paul Proost, Sofie Struyf, Mieke Gouwy, Timothy Devos
      Abstract: BCR::ABL1 negative myeloproliferative neoplasms (MPN) form a distinct group of hematologic malignancies characterized by sustained proliferation of cells from multiple myeloid lineages. With a median survival of 16-35 months in patients with high-risk disease, primary myelofibrosis (PMF) is considered the most aggressive entity amongst all BCR::ABL1 MPN. Additionally, for a significant subset of patients, MPN evolve into secondary acute myeloid leukemia (AML), which has an even poorer prognosis compared to de novo AML. As the exact mechanisms of disease development and progression remain to be elucidated, current therapeutic approaches fail to prevent disease progression or transformation into secondary AML. As each MPN entity is characterized by sustained activation of various immune cells and raised cytokine concentrations within bone marrow (BM) and peripheral blood (PB), MPN may be considered to be typical inflammation-related malignancies. However, the exact role and consequences of increased cytokine concentrations within BM and PB plasma has still not been completely established. Up-regulated cytokines can stimulate cellular proliferation, or contribute to the development of an inflammation-related BM niche resulting in genotoxicity and thereby supporting mutagenesis. The neutrophil chemoattractant CXCL8 is of specific interest as its concentration is increased within PB and BM plasma of patients with PMF. Increased concentration of CXCL8 negatively correlates with overall survival. Furthermore, blockage of the CXCR1/2 axis appears to be able to reduce BM fibrosis and megakaryocyte dysmorphia in murine models. In this review, we summarize available evidence on the role of the CXCL8-CXCR1/2 axis within the pathogenesis of PMF, and discuss potential therapeutic modalities targeting either CXCL8 or its cognate receptors CXCR1/2.
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/β
           response in bone marrow-derived mesenchymal stroma

    • Authors: Mandy W. E. Smeets; Elisabeth M. P. Steeghs, Jan Orsel, Femke Stalpers, Myrthe M. P. Vermeeren, Christina H. J. Veltman, Lotte Slenders, Stefan Nierkens, Cesca van de Ven, Monique L. den Boer
      Abstract: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) can hijack the normal bone marrow microenvironment to create a leukemic niche which facilitates blast cell survival and promotes drug resistance. Bone marrow-derived mesenchymal stromal cells (MSC) mimic this protective environment in ex vivo co-cultures with leukemic cells obtained from children with newly diagnosed BCP-ALL. We examined the potential mechanisms of this protection by RNA sequencing of flow-sorted MSC after co-culture with BCP-ALL cells. Leukemic cells induced an interferon (IFN)-related gene signature in MSC, which was partially dependent on direct cell-cell signaling. The signature was selectively induced by BCP-ALL cells, most profoundly by ETV6-RUNX1-positive ALL cells, as co-culture of MSC with healthy immune cells did not provoke a similar IFN signature. Leukemic cells and MSC both secreted IFNα and IFNβ, but not IFNγ. In line, the IFN gene signature was sensitive to blockade of IFNα/β signaling, but less to that of IFNγ. The viability of leukemic cells and level of resistance to three chemotherapeutic agents was not affected by interference with IFN signaling using selective IFNα/β inhibitors or silencing of IFN-related genes. Taken together, our data suggest that the leukemia-induced expression of IFNα/β-related genes by MSC does not support survival of BCP-ALL cells but may serve a different role in the pathobiology of BCP-ALL.
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • Characterization of zanubrutinib safety and tolerability profile and
           comparison with ibrutinib safety profile in patients with B-cell
           

    • Authors: Jennifer R. Brown; Paolo Ghia, Wojciech Jurczak, Brad S. Kahl, Nicole Lamanna, Tadeusz Robak, Mazyar Shadman, Constantine S. Tam, Lugui Qiu, Jason Paik, Tommi Salmi, Liping Wang, Jun Zhang, Meng Zhang, Aileen Cohen, Han Ma, Alessandra Tedeschi
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • Proteogenomic profiling uncovers differential therapeutic vulnerabilities
           between TCF3::PBX1 and TCF3::HLF translocated B-cell acute lymphoblastic
           leukemia

    • Authors: Lena Blumel; Flavia Bernardi, Daniel Picard, Jacob Torrejon Diaz, Vera H. Jepsen, Rebecca Hasselmann, Julian Schliehe-Diecks, Jasmin Bartl, Nan Qin, Beat Bornhauser, Sanil Bhatia, Blerim Marovka, Veronique Marsaud, Florent Dingli, Damarys Loew, Martin Stanulla, Jean-Pierre Bourqin, Arndt Borkhardt, Marc Remke, Olivier Ayrault, Ute Fischer
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell
           transplant patients at high risk for cytomegalovirus complications:
           evaluation of vaccine safety, immunogenicity and impact on viremia
           requiring antivirals

    • Authors: Corinna La Rosa; Yoonsuh Park, Dongyun Yang, Qiao Zhou, Teodora Kaltcheva, Nicole Karras, Jerry Cheng, Weili Sun, Don J. Diamond, Anna Pawlowska
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute
           lymphoblastic leukemia

    • Authors: Shannon L. Carey-Smith; Maryam H. Simad, Kunjal Panchal, Carlos Aya-Bonilla, Hannah Smolders, Sang Lin, Jesse D. Armitage, Vivien T. Nguyen, Kathryn Bentley, Jette Ford, Sajla Singh, Joyce Oommen, Anouchka P. Laurent, Thomas Mercher, John D. Crispino, Andrew P. Montgomery, Michael Kassiou, Thierry Besson, Emmanuel Deau, Laurent Meijer, Laurence C. Cheung, Rishi S. Kotecha, Sébastien Malinge
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • Mycophenolate mofetil is associated with inferior overall survival in
           cytomegalovirus-seropositive patients with acute myeloid leukemia
           undergoing hematopoietic cell transplantation

    • Authors: Rima M. Saliba; Stephanie J. Lee, Paul A Carpenter, Geoffrey R Hill, Catherine J. Lee, Amin Alousi, May Daher, George Chen, Richard E. Champlin, Katayoun Rezvani, Elizabeth J. Shpall, Rohtesh S. Mehta
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • Health-related quality of life in relapsed/refractory multiple myeloma
           treated with melflufen and dexamethasone: analyses from the phase III
           OCEAN study

    • Authors: Fredrik H. Schjesvold; Heinz Ludwig, Sossana Delimpasi, Pawel Robak, Daniel Coriu, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Meletios-Athanasios Dimopoulos, Tamas Masszi, Natalia G. Chernova, Anna Sandberg, Marcus Thuresson, Stefan Norin, Nicolaas A. Bakker, Maria-Victoria Mateos, Paul G. Richardson, Pieter Sonneveld
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • Evidence for a cytoplasmic proplatelet promoting factor that triggers
           platelet production

    • Authors: Joseph E. Italiano Jr; Kellie R. Machlus
      PubDate: Thu, 29 Feb 2024 00:00:00 +000
       
  • Targeting TNF/IL-17/MAPK pathway in hE2A-PBX1 leukemia: effects of OUL35,
           KJ-Pyr-9, and CID44216842

    • Authors: Haiping Luo; Qiqi Li, Jiaxin Hong, Zhibin Huang, Wenhui Deng, Kunpeng Wei, Siyu Lu, Hailong Wang, Wenqing Zhang, Wei Liu
      Abstract: t(1;19)(q23;p13) is one of the most common translocation genes in childhood acute lymphoblastic leukemia (ALL) and is also present in acute myeloid leukemia (AML) and mixed-phenotype acute leukemia (MPAL). This translocation results in the formation of the oncogenic E2A-PBX1 fusion protein, which contains a trans-activating domain from E2A and a DNA-binding homologous domain from PBX1. Despite its clear oncogenic potential, the pathogenesis of E2A-PBX1 fusion protein is not fully understood (especially in leukemias other than ALL), and effective targeted clinical therapies have not been developed. To address this, we established a stable and heritable zebrafish line expressing human E2A-PBX1 (hE2A-PBX1) for high-throughput drug screening. Blood phenotype analysis showed that hE2A-PBX1 expression induced myeloid hyperplasia by increasing myeloid differentiation propensity of hematopoietic stem cells (HSPC) and myeloid proliferation in larvae, and progressed to AML in adults. Mechanistic studies revealed that hE2A-PBX1 activated the TNF/IL-17/MAPK signaling pathway in blood cells and induced myeloid hyperplasia by upregulating the expression of runx1. Interestingly, through high-throughput drug screening, three small molecules targeting the TNF/IL-17/MAPK signaling pathway were identified, including OUL35, KJ-Pyr-9, and CID44216842, which not only alleviated the hE2A-PBX1-induced myeloid hyperplasia in zebrafish but also inhibited the growth and oncogenicity of human pre-B ALL cells with E2A-PBX1. Overall, this study provides a novel hE2APBX1 transgenic zebrafish leukemia model and identifies potential targeted therapeutic drugs, which may offer new insights into the treatment of E2A-PBX1 leukemia.
      PubDate: Thu, 22 Feb 2024 00:00:00 +000
       
  • Pubertal development of transfusion-dependent thalassemia patients in the
           era of oral chelation with deferasirox: results from the French registry

    • Authors: Mathilde Veneziano Broccia; Julia Vergier, Audrey Benoit, Yoann Huguenin, Anne Lambilliotte, Marie Pierre Castex, Stephanie Gourdon, Ghislaine Ithier, Kamila Kebaili, Pierre Rohrlich, Corinne Pondarre, Abdourahim Chamouine, Pauline Simon, Kokou Placide Agbo Kpati, Slimane Allali, Sandrine Baron-Joly, Sophie Bayart, Nicolas Billaud, Valentine Brousse, Cecile Dumesnil, Nathalie Garnier, Isabelle Guichard, Laure Joseph, Annie Kamdem, Julie Maitre, Catherine Mathey, Catherine Paillard, Aurelie Phulpin, Cecile Renard, Cecile Stoven, Mohamed Touati, Capucine Trochu, Suzanne Mathieu Nafissi, Catherine Badens, Sarah Szepetowski, Isabelle Thuret
      PubDate: Thu, 22 Feb 2024 00:00:00 +000
       
  • Selection of dormant cells during treatment of T-lineage lymphoblastic
           leukemia and CREB as a therapeutic target

    • Authors: Dino Masic; Hayden Bell, Frederik W van Delft, Julie Anne Elizabeth Irving
      PubDate: Thu, 22 Feb 2024 00:00:00 +000
       
  • Belantamab mafodotin: an important treatment option for vulnerable
           patients with triple class exposed relapsed and/or refractory multiple
           myeloma

    • Authors: Maria Victoria Mateos; Katja Weisel, Evangelos Terpos, Sossana Delimpasi, Efstathios Kastritis, Elena Zamagni, Michel Delforge, Enrique Ocio, Eirini Katodritou, Francesca Gay, Alessandra Larocca, Xavier Leleu, Paula Rodriguez Otero, Fredik Schjesvold, Michele Cavo, Meletios A. Dimopoulos
      PubDate: Thu, 22 Feb 2024 00:00:00 +000
       
  • Phenomenon of tumor flare with talquetamab in a patient with
           extramedullary myeloma

    • Authors: Mark Forsberg; Santiago Beltran, Mendel Goldfinger, Murali Janakiram, Deepak Kalbi, Amit Verma, Dennis Cooper, Nishi Shah
      PubDate: Thu, 22 Feb 2024 00:00:00 +000
       
  • Defibrotide improves COVID-19-related acute respiratory distress syndrome
           in myeloma patients after chimeric antigen receptor T-cell treatment
           without compromising virus-specific and anti-myeloma T-cell responses

    • Authors: Mehmet H. Kocoglu; Paul G. Richardson, Clifton C. Mo, Aaron P. Rapoport, Djordje Atanackovic
      PubDate: Thu, 22 Feb 2024 00:00:00 +000
       
  • Indirect treatment comparisons: how to MAIC it right'

    • Authors: Emmanuel Bachy
      PubDate: Thu, 15 Feb 2024 00:00:00 +000
       
  • Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of
           patients with relapsed or refractory multiple myeloma: results of the
           phase II, nonrandomized, multicenter GEM-SELIBORDARA study

    • Authors: Verónica González-Calle; Paula Rodríguez-Otero, Anna Sureda, Felipe de Arriba, Marta Reinoso, Paz Ribas, Ana Pilar González-Rodríguez, Yolanda González, Albert Oriol, Joaquín Martínez-López, Marta Sonia González, Miguel T. Hernández, Maialen Sirvent, Teresa Cedena, Noemí Puig, Bruno Paiva, Joan Bladé, Juan José Lahuerta, Jesús F. San-Miguel, María-Victoria Mateos
      Abstract: The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase II study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd (S-DVd). A total of 57 patients were enrolled in the two parts of the study. Part 1 enrolled a heavily pretreated population with at least three prior lines (PL) of therapy and part 2 enrolled an early relapse population with at least one PL of therapy. The primary endpoint was complete response (CR) rate in part 2 and overall response rate (ORR) in part 1. In the latter, 24 patients were treated with a median of three PL. Overall response rate (ORR) was 50% with two CR. Median progression- free survival (PFS) was 7 months. In part 2, 33 patients were enrolled, with a median of one PL. ORR was 82% and CR or better was 33%. Median PFS was 24 months. In lenalidomide-refractory patients, a median PFS of 22.1 months was observed. Thrombocytopenia was the most common hematological adverse event (69%; grade 3-4: 34%) and nausea, the most frequent non-hematological adverse event (38%; grade 3-4: 6%). Sixty-two percent of the patients required dose modifications. In summary, although the primary endpoint of the study was not met, the combination of S-DVd showed encouraging clinical efficacy with a generally manageable safety profile representing a potential option for the treatment of RRMM patients.
      PubDate: Thu, 15 Feb 2024 00:00:00 +000
       
  • Role of minimal residual disease assessment in multiple myeloma

    • Authors: Raphael Szalat; Kenneth Anderson, Nikhil Munshi
      Abstract: Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including monoclonal antibodies, bispecific T-cell engagers and chimeric antigen receptor T cells (CAR T cells), most MM patients now have a prolonged survival. However, the disease remains incurable, and a subgroup of high-risk patients continue to have early relapse and short survival. Novel and highly sensitive methods have been developed allowing the detection of minimal residual disease (MRD) during or after treatment. Achievement of MRD negativity is a strong and independent prognostic factor in both prospective randomized clinical trials and in the real-world setting. While MRD assessment is now a validated endpoint in clinical trials, its incorporation in clinical practice is not yet established and its potential impact on guiding therapy remains under in-depth evaluation. Here we discuss the different methods available for MRD assessment and the role of MRD evaluation in MM management.
      PubDate: Thu, 08 Feb 2024 00:00:00 +000
       
  • Phosphatase, Mg2+/Mn2+ dependent 1B regulates the hematopoietic stem cells
           homeostasis via the Wnt/β-catenin signaling

    • Authors: Zhiyuan Lu; Hanzhi Yu, Yanxia Li, Guangsen Xu, Xiaoxun Li, Yongjun Liu, Yuemao Shen, Zhigang Cai, Baobing Zhao
      Abstract: Hematopoietic stem cells (HSC) are primarily dormant in a cell-cycle quiescence state to preserve their self-renewal capacity and long-term maintenance. How HSC maintain the balance between activation and quiescence remains largely unknown. Herein, we found that phosphatase, Mg2+/Mn2+ dependent 1B (Ppm1b) is required for the expansion of phenotypic HSC in vitro. By using a conditional knockout mouse model in which Ppm1b was specifically depleted in hematopoietic cells, we demonstrated that loss of Ppm1b impaired the HSC homeostasis and hematopoietic reconstitution. Ppm1b deficiency mice also exhibited B-cell leukocytopenia, which is due to the compromised commitment and proliferation of B-biased lymphoid progenitor cells from common lymphoid progenitors. With the aid of a small molecular inhibitor, we confirmed the roles of Ppm1b in adult hematopoiesis that phenocopied the effects with loss of Ppm1b. Furthermore, transcriptome profiling of Ppm1b-deficient HSC revealed the disruptive quiescence of HSC. Mechanistically, Ppm1b interacted with β-catenin and mediated its dephosphorylation. Loss of Ppm1b led to the decrease in the active β-catenin (non-phosphorylated) that interrupted the Wnt/β-catenin signaling in HSC, which consequently suppressed HSC expansion. Together, our study identified an indispensable role for Ppm1b in regulating HSC homeostasis via the Wnt/β-catenin pathway.
      PubDate: Thu, 08 Feb 2024 00:00:00 +000
       
  • Patterns of lower risk myelodysplastic syndrome progression: factors
           predicting progression to high-risk myelodysplastic syndrome and acute
           myeloid leukemia

    • Authors: Akriti G. Jain; Somedeb Ball, Luis Aguirre, Najla Al Ali, David Kaldas, Sara Tinsley-Vance, Andrew Kuykendall, Onyee Chan, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami Komrokji
      Abstract: The patterns of low-risk myelodysplastic syndrome (MDS) progression and the clinical and molecular features of those patterns have not been well described. We divided our low-risk (LR) MDS patients (N=1,914) into 4 cohorts: 1) patients who remained LR-MDS (LR-LR; N=1,300; 68%), 2) patients who progressed from LR to high-risk (HR) MDS (LR-HR) without transformation into acute myeloid leukemia (AML) (N=317; 16.5%), 3) patients who progressed from LR to HR MDS and then AML (LR-HR-AML; N=124; 6.5%), and 4) patients who progressed from LR MDS directly to AML (LR-AML; N=173; 9%). Risk factors for progression included: male gender, low absolute neutrophil count (ANC), low platelet count, high bone marrow (BM) blasts, ferritin >1000 mcg/L, albumin <3.5 g/dL, multi-lineage dysplasia (MLD), and lack of ring sideroblasts. Among patients with marked BM fibrosis (N=49), 18% progressed directly to AML. Somatic mutations (SM) associated with an increased risk of direct or indirect AML progression included SRSF2 and NRAS. SM in IDH1, IDH2 and NPM1 were more common in patients with direct AML transformation. SM associated with progression to higher risk disease only, without AML transformation, were ASXL1, TP53, RUNX1, and CBL. SF3B1 mutation was associated with less progression. About 171 patients (13.1% of all LR-LR patients) died within two years of diagnosis of LR-MDS without disease progression. Among the 61 cases with documented cause of death, 18 patients (29.5%) died from cytopenia and MDS-related complications. Identifying patterns of disease progression of LR MDS patients and their predictive factors will be crucial to be able to tailor therapy accordingly.
      PubDate: Thu, 01 Feb 2024 00:00:00 +000
       
  • Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in
           patients with relapsed and refractory multiple myeloma: final overall
           survival analysis

    • Authors: Paul G. Richardson; Aurore Perrot, Jesus San Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Shang-Yi Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, Mony Chenda Morisse, Kenneth C. Anderson
      Abstract: The primary and prespecified updated analyses of ICARIA-MM (clinicaltrial gov. Identifier: NCT02990338) demonstrated improved progression-free survival (PFS) and a benefit in overall survival (OS) was reported with the addition of isatuximab, an anti-CD38 monoclonal antibody, to pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma. Here, we report the final OS analysis. This multicenter, randomized, open-label, phase III study included patients who had received and failed ≥2 previous therapies, including lenalidomide and a proteasome inhibitor. Between January 10, 2017, and February 2, 2018, 307 patients were randomized (1:1) to isatuximab-pomalidomide-dexamethasone (Isa-Pd; N=154) or Pd (N=153), stratified based on age (<75 vs. ≥75 years) and number of previous lines of therapy (2-3 vs. >3). At data cutoff for the final OS analysis after 220 OS events (January 27, 2022), median follow-up duration was 52.4 months. Median OS was 24.6 months (95% confidence interval [CI]: 20.3-31.3) with Isa-Pd and 17.7 months (95% CI: 14.4- 26.2) with Pd (hazard ratio=0.78; 95% CI: 0.59-1.02; 1-sided P=0.0319). Despite subsequent daratumumab use in the Pd group and its potential benefit on PFS in the first subsequent therapy line, median PFS2 was significantly longer with Isa-Pd versus Pd (17.5 vs. 12.9 months; log-rank 1-sided P=0.0091). In this analysis, Isa-Pd continued to be efficacious and well tolerated after follow-up of approximately 52 months, contributing to a clinically meaningful, 6.9-month improvement in median OS in patients with relapsed/refractory multiple myeloma.
      PubDate: Thu, 01 Feb 2024 00:00:00 +000
       
  • GPIbα CAAR T cells function like a Trojan horse to eliminate autoreactive
           B cells to treat immune thrombocytopenia

    • Authors: Jie Zhou; Yanyan Xu, Jinhui Shu, Haojie Jiang, Linlin Huang, Min Xu, Junling Liu, Yu Hu, Heng Mei
      Abstract: Breakthrough treatment for refractory and relapsed immune thrombocytopenia (ITP) patients is urgently needed. Autoantibody- mediated platelet clearance and megakaryocyte dysfunction are important pathogenic mediators of ITP. Glycoprotein (GP) Ibα is a significant autoantigen found in ITP patients and is associated with poor response to standard immunosuppressive treatments. Here, we engineered human T cells to express a chimeric autoantibody receptor (CAAR) with GPIbα constructed into the ligand-binding domain fused to the CD8 transmembrane domain and CD3ζ-4-1BB signaling domains. We performed cytotoxicity assays to assess GPIbα CAAR T-cell selective cytolysis of cells expressing anti-GPIbα B-cell receptors in vitro. Furthermore, we demonstrated the potential of GPIbα CAAR T cells to persist and precisely eliminate GPIbα-specific B cells in vivo. In summary, we present a proof of concept for CAAR T-cell therapy to eradicate autoimmune B cells while sparing healthy B cells with GPIbα CAAR T cells that function like a Trojan horse. GPIbα CAAR T-cell therapy is a promising treatment for refractory and relapsed ITP patients.
      PubDate: Thu, 01 Feb 2024 00:00:00 +000
       
  • The clonal hydra: neoantigen-specific T-cell response in germ cell tumors

    • Authors: Shefali Mehra; Justin Taylor
      PubDate: Thu, 25 Jan 2024 00:00:00 +000
       
  • Harnessing the cytotoxic granule exocytosis to augment the efficacy of
           T-cell-engaging bispecific antibody therapy

    • Authors: Mika Casey; Carol Lee, Sharon M. Hoyte, Rebecca L. Johnston, Wing Yu Kwok, Soi Cheng Law, Maher K. Gandhi, Simon J. Harrison, Kyohei Nakamura
      Abstract: T-cell-engaging bispecific antibody (T-BsAb, also known as BiTE) therapy has emerged as a powerful therapeutic modality against multiple myeloma. Given that T-BsAb therapy redirects endogenous T cells to eliminate tumor cells, reinvigorating dysfunctional T cells may be a potential approach to improve the efficacy of T-BsAb. While various immunostimulatory cytokines can potentiate effector T-cell functions, the optimal cytokine treatment for T-BsAb therapy is yet to be established, partly due to a concern of cytokine release syndrome driven by aberrant interferon (IFN)-γ production. Here, we functionally screen immunostimulatory cytokines to determine an ideal combination partner for T-BsAb therapy. This approach reveals interleukin (IL)-21 as a potential immunostimulatory cytokine with the ability to augment T-BsAb-mediated release of granzyme B and perforin, without increasing IFN-γ release. Transcriptome profiling and functional characterization strongly support that IL-21 selectively targets the cytotoxic granule exocytosis pathway, but not pro-inflammatory responses. Notably, IL-21 modulates multiple steps of cytotoxic effector functions including upregulation of co-activating CD226 receptor, increasing cytotoxic granules, and promoting cytotoxic granule delivery at the immunological synapse. Indeed, T-BsAb-mediated myeloma killing is cytotoxic granule-dependent, and IL-21 priming significantly augments cytotoxic activities. Furthermore, in vivo IL-21 treatment induces cytotoxic effector reprogramming in bone marrow T cells, showing synergistic anti-myeloma effects in combination with T-BsAb therapy. Together, harnessing the cytotoxic granule exocytosis pathway by IL-21 may be a potential approach to achieve better responses by T-BsAb therapy.
      PubDate: Thu, 25 Jan 2024 00:00:00 +000
       
  • Genomic landscape of patients in a phase II study of zanubrutinib in
           ibrutinib- and/or acalabrutinib-intolerant patients with B-cell
           malignancies

    • Authors: Linlin Xu; Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul D. Gandhi, Rocco Crescenzo, Kunthel By, Aileen Cohen, Dih-Yih Chen, Adam Idoine, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
      PubDate: Thu, 25 Jan 2024 00:00:00 +000
       
  • Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory
           mature B-cell tumors

    • Authors: Yuqin Song; Junning Cao, Qingyuan Zhang, Caixia Li, Lugui Qiu, Junyuan Qi, Huilai Zhang, Wenyu Li, Lihong Liu, Hongmei Jing, Keshu Zhou, Weijing Zhang, Liling Zhang, Daqi Li, Liqun Zou, Haiyan Yang, Wenbin Qian, Hui Zhou, Jianda Hu, Hongyan Yin, Sisi Fu, Songhua Fan, Qian Xu, Jian Wang, Xiaoyun Jia, Guangxiu Dai, Weiguo Su, Jun Zhu
      Abstract: Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor with anti-tumor activity in preclinical models of B-cell malignancy. We conducted a dose-escalation and dose-expansion phase I study of sovleplenib in patients with relapsed/ refractory mature B-cell tumors. Dose escalation followed a 3+3 design; patients received oral sovleplenib (200-800 mg once daily [q.d.] or 200 mg twice daily [b.i.d.], 28-day cycles). During dose expansion, patients were enrolled into four cohorts per lymphoma classification and treated at the recommended phase II dose (RP2D) (clinicaltrials gov. Identifier: NCT02857998). Overall, 134 Chinese patients were enrolled (dose escalation, N=27; dose expansion, N=107). Five patients experienced dose-limiting toxicities: one each of amylase increased (200 mg q.d.), febrile neutropenia (800 mg q.d.), renal failure (800 mg q.d.), hyperuricemia and blood creatine phosphokinase increased (200 mg b.i.d.) and blood bilirubin increased and pneumonia (200 mg b.i.d.). RP2D was determined as 600 mg (>65 kg) or 400 mg (≤65 kg) q.d.. The primary efficacy end point of independent review committee-assessed objective response rate in indolent B-cell lymphoma was 50.8% (95% confidence interval: 37.5- 64.1) in 59 evaluable patients at RP2D (follicular lymphoma: 60.5%, marginal zone lymphoma: 28.6%, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, 0%). The most common (≥10% patients) grade ≥3 treatment-related adverse events in the dose-expansion phase were decreased neutrophil count (29.9%), pneumonia (12.1%) and decreased white blood cell count (11.2%). Pharmacokinetic exposures increased dose-proportionally with ascending dose levels from 200-800 mg, without observed saturation. Sovleplenib showed anti-tumor activity in relapsed/refractory B-cell lymphoma with acceptable safety. Further studies are warranted.
      PubDate: Thu, 18 Jan 2024 00:00:00 +000
       
  • Autologous stem cell transplant in fit patients with refractory or early
           relapsed diffuse large B-cell lymphoma that responded to salvage
           chemotherapy

    • Authors: Aung M. Tun; Yucai Wang, Seth Maliske, Ivana Micallef, David J. Inwards, Thomas M. Habermann, Luis Porrata, Jonas Paludo, Jose Villasboas Bisneto, Allison Rosenthal, Mohamed A Kharfan-Dabaja, Stephen M. Ansell, Grzegorz S. Nowakowski, Umar Farooq, Patrick B. Johnston
      Abstract: Chimeric antigen receptor T-cell therapy is the new standard of care in fit patients with refractory or early relapsed diffuse large B-cell lymphoma (DLBCL). However, there may still be a role for salvage chemotherapy (ST) and autologous stem cell transplant (ASCT) in certain circumstances (e.g., lack of resources for chimeric antigen receptor T-cell therapy, chemosensitive relapses). We retrospectively studied 230 patients with refractory or early relapsed DLBCL who underwent ST and ASCT. The median line of ST was one (range, 1-3). Best response before ASCT was complete response in 106 (46%) and partial response in 124 (54%) patients. The median follow-up after ASCT was 89.4 months. The median progression-free (PFS) and overall survival (OS) were 16.1 and 43.3 months, respectively. Patients relapsing between 6 to 12 months after frontline therapy had a numerically better median PFS (29.6 months) and OS (88.5 months). Patients who required one line of ST, compared to those requiring more than one line, had a better median PFS (37.9 vs. 3.9 months; P=0.0005) and OS (68.3 vs. 12.0 months; P=0.0005). Patients who achieved complete response had a better median PFS (71.1 vs. 6.3 months; P<0.0001) and OS (110.3 vs. 18.9 months; P<0.0001) than those in partial response. Patients who achieved complete response after one line of ST had the most favorable median PFS (88.5 months) and OS (117.2 months). Post-ASCT survival outcomes of patients with refractory or early relapsed DLBCL appeared reasonable and were particularly favorable in those who required only one line of ST to achieve complete response before ASCT, highlighting the role of this procedure in select patients with chemosensitive disease.
      PubDate: Thu, 18 Jan 2024 00:00:00 +000
       
  • Carfilzomib, thalidomide, and dexamethasone are safe and effective in
           relapsed and/or refractory multiple myeloma: final report of the
           single-arm, multicenter, phase II ALLG MM018/AMN002 study

    • Authors: Slavisa Ninkovic; Simon J Harrison, Je-Jung Lee, Nick Murphy, Jae Hoon Lee, Jane Estell, Vivien M Chen, Noemi Horvath, Kihuyn Kim, Richard Eek, Bradley Augustson, Soo-Mee Bang, Shang-Yi Huang, Rajeev Rajagopal, Ferenc Szabo, Daniel Engeler, Belinda E Butcher, Peter Mollee, Brian Durie, Wee Joo Chng, Hang Quach
      Abstract: This multicenter, phase II study of the Australasian Lymphoma and Leukemia Group and the Asian Myeloma Network investigated fixed-duration (18-month) treatment with carfilzomib (K), thalidomide (T), and dexamethasone (d) (KTd) in patients with relapsed and/or refractory multiple myeloma who had received one to three prior lines of therapy. Patients received induction with up to 12 28-day cycles of carfilzomib (20 mg/m2 intravenously in cycle 1 on days 1 and 2, then 56 mg/m2 [36 mg/m2 for patients ≥75 years] from day 8 onwards), thalidomide 100 mg orally in the evening and weekly dexamethasone 40 mg (20 mg for patients ≥75 years). During maintenance, thalidomide was omitted, while carfilzomib was continued on days 1, 2, 15, and 16 with fortnightly dexamethasone. The primary endpoint was progression-free survival. Secondary endpoints were overall response rate, overall survival, duration of response, safety, and tolerability. Ninety-three patients (median age 66.3 years [range, 41.9-84.5]) were enrolled and followed up for a median of 26.4 months (range, 1.6-54.6). The median progression-free survival was 22.3 months (95% confidence interval: 15.7-25.6) and the 2-year progression-free survival was 46.3% (95% confidence interval: 35.1-52.8). The median overall survival was not reached and the 2-year overall survival was 73.8% (95% confidence interval: 62.9-81.9). The overall response rate was 88% (73% had a very good partial response or better). There was no difference in the depth of response, progression-free survival or overall survival comparing Asian and non-Asian cohorts (P=0.61). The safety profile of KTd was consistent with that of each individual drug. KTd is well tolerated and effective in patients with relapsed and/or refractory multiple myeloma irrespective of Asian or non-Asian ethnicity and provides an alternative treatment option, particularly in circumstances in which the use of carfilzomib, lenalidomide, and dexamethasone (KRd) is limited by access, cost, or renal impairment.
      PubDate: Thu, 18 Jan 2024 00:00:00 +000
       
  • Evaluation of the genetic basis of familial-associated early-onset
           hematologic cancers in an ancestral/ethnically diverse population

    • Authors: Qianxi Feng; Keren Xu, Mancy Shah, Shaobo Li, Andrew D. Leavitt, Lucy A. Godley, Adam J. de Smith, Joseph L. Wiemels
      Abstract: Genetic predisposition to hematologic malignancies has historically been addressed utilizing patients recruited from clinical trials and pedigrees constructed at major treatment centers. Such efforts leave unexplored the genetic basis of variations in risk by race/ethnic group shown in population-based surveillance data where cancer registration, compulsory by law, delivers universal enrollment. To address this, we performed exome sequencing on DNA isolated from newborn bloodspots derived from sibling pairs with early-onset cancers across California in which at least one of the siblings developed a hematologic cancer, using unbiased recruitment from the full state population. We identified pathogenic/likely pathogenic (P/ LP) variants among 1,172 selected cancer genes that were private or present at low allele frequencies in reference populations. Within 64 subjects from 32 families, we found 9 LP variants shared between siblings, and an additional 7 such variants in singleton children (not shared with their sibling). In 8 of the shared cases, the ancestral origin of the local haplotype that carries P/LP variants matched the dominant global ancestry of study participant families. This was the case for Latino sibling pairs on FLG and CBLB, non-Latino White sibling pairs in TP53 and NOD2, and a shared GATA2 variant for a non-Latino Black sibling pair. A new inherited mutation in HABP2 was identified in a sibling pair, one with diffuse large B-cell lymphoma and the other with neuroblastoma. Overall, the profile of P/LP germline variants across ancestral/ethnic groups suggests that rare alleles contributing to hematologic diseases originate within their race/ethnic origin parental populations, demonstrating the value of this discovery process in diverse, population-based registries.
      PubDate: Thu, 11 Jan 2024 00:00:00 +000
       
  • Longitudinal, natural history study reveals the disease burden of
           idiopathic multicentric Castleman disease

    • Authors: Mateo Sarmiento Bustamante; Sheila K. Pierson, Yue Ren, Adam Bagg, Joshua D. Brandstadter, Gordan Srkalovic, Natalie Mango, Daisy Alapat, Mary Jo Lechowicz, Hongzhe Li, Frits van Rhee, Megan S. Lim, David C. Fajgenbaum
      Abstract: Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder with heterogeneous presentations ranging from moderate constitutional symptoms to life-threatening multiorgan system involvement. There are vastly different clinical subtypes, with some patients demonstrating thrombocytopenia, anasarca, fever/elevated C-reactive protein, reticulin fibrosis/renal failure, and organomegaly (TAFRO) and others having milder/more moderate symptoms with potential for severe disease (not otherwise specified, NOS). Due to its rarity and heterogeneity, the natural history and long-term burden of iMCD are poorly understood. We investigated real-world medical data from ACCELERATE, a large natural history registry of patients with Castleman disease, to better characterize the long-term disease burden experienced by these patients. We found that iMCD-TAFRO patients face a significant hospitalization burden, requiring more time in the hospital than iMCDNOS patients during the year surrounding diagnosis (median [interquartile range]: 36 [18-61] days vs. 0 [0-4] days; P<0.001). In addition, we found life-sustaining interventions, such as mechanical ventilation (17%) and dialysis (27%), were required among iMCD patients, predominantly those with iMCD-TAFRO. iMCD-NOS patients, however, spent a significantly greater proportion of time following disease onset in a state of disease flare (median 52.3% vs. 18.9%; P=0.004). Lastly, we observed severe iMCD-related morbidities, such as acute renal failure, sepsis and pneumonia, among others, arising after iMCD diagnosis, impairing the patients’ quality of life. These data demonstrate a substantial disease burden experienced by iMCD patients and emphasize the importance of ongoing research into iMCD to aid disease control.
      PubDate: Thu, 11 Jan 2024 00:00:00 +000
       
  • Elucidation of molecular basis of osteolytic bone lesions in advanced
           multiple myeloma

    • Authors: Dongyeop Shin; Myung-Jin Kim, Soyeon Chun, Dongchan Kim, Chansu Lee, Kwang-Sung Ahn, Eunyoung Jung, Dayeon Kim, Byung-Chul Lee, Daehee Hwang, Yonghwan Kim, Sung-Soo Yoon
      Abstract: Osteolytic bone lesion is a major cause of lower quality of life and poor prognosis in patients with multiple myeloma (MM), but molecular pathogenesis of the osteolytic process in MM remains elusive. Fms-like tyrosine kinase 3 ligand (FLT3L) was reported to be elevated in bone marrow (BM) and blood of patients with advanced MM who often show osteolysis. Here, we investigated a functional link of FLT3L to osteolytic process in MM. We recruited 86, 306, and 52 patients with MM, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL), respectively. FLT3L levels of patients with hematologic malignancies were measured in BM-derived plasma and found to be significantly higher in MM than in AML or ALL, which rarely show osteolysis. FLT3L levels were further elevated in MM patients with bone lesion compared with patients without bone lesion. In vitro cell-based assays showed that the administration of FLT3L to HEK293T, HeLa, and U2OS cells led to an increase in the DKK1 transcript level through STAT3 phosphorylation at tyrosine 705. WNT reporter assay showed that FLT3L treatment reduced WNT signaling and nuclear translocation of β-catenin. These results collectively show that the FLT3L-STAT3-DKK1 pathway inhibits WNT signaling-mediated bone formation in MM, which can cause osteolytic bone lesion. Finally, transcriptomic profiles revealed that FLT3L and DKK1 were predominantly elevated in the hyperdiploidy subtype of MM. Taken together, FLT3L can serve as a promising biomarker for predicting osteolytic bone lesion and also a potential therapeutic target to prohibit the progression of the osteolytic process in MM with hyperdiploidy.
      PubDate: Thu, 11 Jan 2024 00:00:00 +000
       
  • Prior cancer and risk of monoclonal gammopathy of undetermined
           significance: a population-based study in Iceland and Sweden

    • Authors: Sæmundur Rögnvaldsson; Sigrun Thorsteinsdóttir, Elisavet Syriopoulou, Ingigerdur Sverrisdottir, Ingemar Turesson, Elias Eythorsson, Jon Thorir Oskarsson, Thorir Einarsson Long, Brynjar Vidarsson, Pall Torfi Onundarson, Bjarni A. Agnarsson, Margret Sigurdardottir, Isleifur Olafsson, Ingunn Thorsteinsdottir, Thor Aspelund, Gauti Kjartan Gislason, Andri Olafsson, Jon Kristinn Sigurdsson, Malin Hultcrantz, Brian G. M. Durie, Stephen Harding, Magnus Bjorkholm, Ola Landgren, Thorvardur Jon Love, Sigurdur Yngvi Kristinsson
      Abstract: There is some evidence that a prior cancer is a risk factor for the development of multiple myeloma (MM). If this is true, prior cancer should be associated with a higher prevalence or increased progression rate of monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM and related disorders. Those with a history of cancer might therefore constitute a target population for MGUS screening. This two-part study is the first study to evaluate a relationship between MGUS and prior cancers. First, we evaluated whether prior cancers were associated with having MGUS at the time of screening in the Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) study that includes 75,422 individuals screened for MGUS. Next, we evaluated the association of prior cancer and the progression of MGUS to MM and related disorders in a population-based cohort of 13,790 Swedish individuals with MGUS. A history of prior cancer was associated with a modest increase in the risk of MGUS (odds ratio=1.10; 95% confidence interval: 1.00-1.20). This excess risk was limited to prior cancers in the year preceding MGUS screening. A history of prior cancer was associated with progression of MGUS, except for myeloid malignancies which were associated with a lower risk of progression (hazard ratio=0.37; 95% confidence interval: 0.16-0.89; P=0.028). Our findings indicate that a prior cancer is not a significant etiological factor in plasma cell disorders. The findings do not warrant MGUS screening or different management of MGUS in those with a prior cancer.
      PubDate: Thu, 11 Jan 2024 00:00:00 +000
       
  • Matched unrelated donor transplantation versus haploidentical
           transplantation with post-transplant cyclophosphamide in children with
           acute myeloid leukemia: a PDWP-EBMT study

    • Authors: Annalisa Ruggeri; Nicole Santoro, Jacques-Emmanuel Galimard, Krzysztof Kalwak, Mattia Algeri, Ludmila Zubarovskaya, Krzysztof Czyzewski, Elena Skorobogatova, Petr Sedlacek, Caroline Besley, Adriana Balduzzi, Yves Bertrand, Julia Peristeri, Franca Fagioli, Mariane Ifversen, Jolanta Gozdzik, Christina Peters, Birgitta Versluijs, Alessandra Biffi, Arcangelo Prete, Maura Faraci, Ibrahim Ghemlas, Ivana Bodova, Olga Aleinikova, Arnaud Dalissier, Vanderson Rocha, Selim Corbacioglu
      Abstract: In children with acute myeloid leukemia (AML) who lack a human leukocyte antigen (HLA) identical sibling, the donor can be replaced with an HLA-matched unrelated donor (MUD) or a haploidentical donor (haplo). We compared outcomes of patients <18 years with AML in first and second complete remission (CR1 & CR2) undergoing a hematopoietic stem cell transplantation (HCT) either with a MUD with anti-thymocyte globulin (ATG) (N=420) or a haplo HCT with post-transplant cyclophosphamide (PT-CY) (N=96) after a myeloablative conditioning regimen (MAC) between 2011 and 2021, reported to the European Society for Blood and Marrow Transplantation. A matched pair analysis was performed to adjust for differences among groups. The final analysis was performed on 253 MUD and 95 haplo-HCT. In the matched cohort, median age at HCT was 11.2 and 10 years and median year of HCT was 2017 and 2018, in MUD and haplo-HCT recipients, respectively. The risk of grade III-IV acute graft-versus-host disease (aGVHD) was significantly higher in the haplo group (hazard ratio [HR]=2.33, 95% confidence interval [CI]: 1.18-4.58; P=0.01). No significant differences were found in 2 years overall survival (OS; 78.4% vs. 71.5%; HR=1.39, 95% CI: 0.84-2.31; P=0.19), leukemia-free survival (LFS; 72.7% vs. 69.5%; HR=1.22, 95% CI: 0.76-1.95; P=0.41), CI of relapse (RI; 19.3% vs. 19.5%; HR=1.14, 95% CI: 0.62-2.08; P=0.68) non-relapse-mortality (NRM; 8% vs. 11%; HR=1.39, 95% CI: 0.66-2.93; P=0.39) and graft-versus-host free relapse-free survival (GRFS; 60.7% vs. 54.5%, HR=1.38, 95% CI: 0.95-2.02; P=0.09) after MUD and haplo-HCT respectively. Our study suggests that haplo-HCT with PT-CY is a suitable option to transplant children with AML lacking a matched related donor.
      PubDate: Thu, 04 Jan 2024 00:00:00 +000
       
  • Neoantigen-specific T-cell response after donor lymphocyte infusion
           associates with favorable outcome in a patient with i(12p) germ cell
           tumor, acute leukemia and sarcoma of the same clonal origin

    • Authors: Vassilis Genoud; Valérie Dutoit, Nhu-Nam Tran Thang, Andrew Janowczyk, Thomas McKee, Yves Chalandon, Petros Tsantoulis, Pierre-Yves Dietrich
      PubDate: Thu, 04 Jan 2024 00:00:00 +000
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.213.60.33
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-
JournalTOCs
 
 
  Subjects -> MEDICAL SCIENCES (Total: 8186 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (205 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (19 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (227 journals)
    - DENTISTRY (266 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (178 journals)
    - GERONTOLOGY AND GERIATRICS (125 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (178 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (90 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2230 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (135 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (150 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (153 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (182 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (151 journals)

HEMATOLOGY (160 journals)                     

Showing 1 - 122 of 122 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 3)
Adipocyte     Open Access  
Advances in Hematology     Open Access   (Followers: 13)
Africa Sanguine     Full-text available via subscription  
American Journal of Hematology     Hybrid Journal   (Followers: 46)
Anemia     Open Access   (Followers: 6)
Annals of Hematology     Hybrid Journal   (Followers: 14)
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 25)
Artery Research     Hybrid Journal   (Followers: 4)
Artificial Cells, Nanomedicine and Biotechnology     Hybrid Journal   (Followers: 3)
ASAIO Journal     Hybrid Journal   (Followers: 2)
Best Practice & Research Clinical Haematology     Hybrid Journal   (Followers: 5)
Blood     Hybrid Journal   (Followers: 296)
Blood Advances     Open Access   (Followers: 9)
Blood and Lymphatic Cancer : Targets and Therapy     Open Access   (Followers: 7)
Blood Cancer Journal     Open Access   (Followers: 21)
Blood Cells, Molecules, and Diseases     Hybrid Journal   (Followers: 5)
Blood Coagulation & Fibrinolysis     Hybrid Journal   (Followers: 27)
Blood Pressure     Open Access   (Followers: 1)
Blood Pressure Monitoring     Hybrid Journal   (Followers: 2)
Blood Reviews     Hybrid Journal   (Followers: 20)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 23)
Bone Marrow Transplantation     Hybrid Journal   (Followers: 15)
British Journal of Haematology     Hybrid Journal   (Followers: 54)
Canadian Journal of Diabetes     Hybrid Journal   (Followers: 9)
Case Reports in Hematology     Open Access   (Followers: 10)
Clinical and Applied Thrombosis/Hemostasis     Open Access   (Followers: 28)
Clinical Diabetes     Full-text available via subscription   (Followers: 30)
Clinical Diabetes and Endocrinology     Open Access   (Followers: 14)
Clinical Lymphoma & Myeloma     Full-text available via subscription   (Followers: 2)
Conquest : The Official Journal of Diabetes Australia     Full-text available via subscription   (Followers: 1)
Current Angiogenesis     Hybrid Journal   (Followers: 1)
Current Diabetes Reports     Hybrid Journal   (Followers: 14)
Current Diabetes Reviews     Hybrid Journal   (Followers: 13)
Current Hematologic Malignancy Reports     Hybrid Journal   (Followers: 2)
Current Opinion in Hematology     Hybrid Journal   (Followers: 14)
Cytotherapy     Full-text available via subscription   (Followers: 1)
Der Diabetologe     Hybrid Journal  
Diabetes     Full-text available via subscription   (Followers: 262)
Diabetes aktuell     Hybrid Journal   (Followers: 2)
Diabetes and Vascular Disease Research     Hybrid Journal   (Followers: 8)
Diabetes Care     Full-text available via subscription   (Followers: 285)
Diabetes Case Reports     Open Access  
Diabetes Educator     Hybrid Journal   (Followers: 10)
Diabetes Research and Clinical Practice     Hybrid Journal   (Followers: 18)
Diabetes Spectrum     Full-text available via subscription   (Followers: 14)
Diabetes Technology & Therapeutics     Hybrid Journal   (Followers: 8)
Diabetes Therapy     Open Access   (Followers: 13)
Diabetic Foot & Ankle     Open Access   (Followers: 9)
Diabetic Medicine     Hybrid Journal   (Followers: 93)
Diabetologia     Hybrid Journal   (Followers: 107)
Diabetologie und Stoffwechsel     Hybrid Journal  
Egyptian Journal of Hematology and Bone Marrow Transplantation     Open Access   (Followers: 9)
eJHaem     Open Access   (Followers: 1)
European Journal of Haematology     Hybrid Journal   (Followers: 12)
Experimental Hematology     Hybrid Journal   (Followers: 3)
Experimental Hematology & Oncology     Open Access   (Followers: 6)
Expert Review of Hematology     Hybrid Journal   (Followers: 4)
Fluids and Barriers of the CNS     Open Access   (Followers: 1)
Haematologica - the Hematology journal     Open Access   (Followers: 35)
Haemophilia     Hybrid Journal   (Followers: 15)
Hematologia     Full-text available via subscription   (Followers: 3)
Hematology     Open Access   (Followers: 9)
Hematology, Transfusion and Cell Therapy     Open Access   (Followers: 2)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 3)
Immunohematology : Journal of Blood Group Serology and Molecular Genetics     Hybrid Journal   (Followers: 3)
Indian Journal of Hematology and Blood Transfusion     Hybrid Journal   (Followers: 1)
Info Diabetologie     Full-text available via subscription  
InFo Hämatologie + Onkologie : Interdisziplinäre Fortbildung von Ärzten für Ärzte     Full-text available via subscription  
Integrated Blood Pressure Control     Open Access   (Followers: 1)
International Blood Research & Reviews     Open Access  
International Journal of Clinical Transfusion Medicine     Open Access   (Followers: 3)
International Journal of Diabetes in Developing Countries     Hybrid Journal   (Followers: 5)
International Journal of Diabetes Research     Open Access   (Followers: 6)
International Journal of Hematology     Hybrid Journal   (Followers: 3)
International Journal of Hematology Research     Open Access   (Followers: 2)
International Journal of Laboratory Hematology     Hybrid Journal   (Followers: 24)
JMIR Diabetes     Open Access  
Journal of Blood Medicine     Open Access  
Journal of Cerebral Blood Flow & Metabolism     Hybrid Journal   (Followers: 3)
Journal of Diabetes     Open Access   (Followers: 12)
Journal of Diabetes and its Complications     Hybrid Journal   (Followers: 13)
Journal of Diabetes and Metabolic Disorders     Open Access   (Followers: 6)
Journal of Diabetes Investigation     Open Access   (Followers: 6)
Journal of Diabetes Mellitus     Open Access   (Followers: 4)
Journal of Hematological Malignancies     Open Access  
Journal of Hematology and Transfusion Medicine     Open Access   (Followers: 1)
Journal of Hematopathology     Hybrid Journal   (Followers: 3)
Journal of Pediatric Hematology/Oncology     Hybrid Journal   (Followers: 6)
Journal of Social Health and Diabetes     Open Access  
Journal of Thrombosis and Haemostasis     Hybrid Journal   (Followers: 52)
Journal of Thrombosis and Thrombolysis     Hybrid Journal   (Followers: 30)
Leukemia     Hybrid Journal   (Followers: 23)
Leukemia and Lymphoma     Hybrid Journal   (Followers: 13)
Leukemia Research     Hybrid Journal   (Followers: 9)
Leukemia Research Reports     Open Access   (Followers: 1)
Leukemia Supplements     Full-text available via subscription  
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Nutrition & Diabetes     Open Access   (Followers: 18)
Oncohematology     Open Access   (Followers: 1)
Open Diabetes Journal     Open Access  
Open Hematology Journal     Open Access   (Followers: 1)
Open Hypertension Journal     Open Access  
Open Journal of Blood Diseases     Open Access  
Pediatric Blood & Cancer     Hybrid Journal   (Followers: 6)
Pediatric Hematology Oncology Journal     Open Access   (Followers: 3)
Peritoneal Dialysis International     Hybrid Journal  
Plasmatology     Open Access   (Followers: 1)
Platelets     Hybrid Journal   (Followers: 2)
Practical Diabetes     Hybrid Journal   (Followers: 4)
Primary Care Diabetes     Hybrid Journal   (Followers: 16)
Research and Practice in Thrombosis and Haemostasis     Open Access   (Followers: 2)
Revista Cubana de Hematología, Inmunología y Hemoterapia     Open Access  
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Seminars in Thrombosis and Hemostasis     Hybrid Journal   (Followers: 28)
The Lancet Haematology     Full-text available via subscription   (Followers: 43)
Therapeutic Advances in Hematology     Hybrid Journal  
Thrombosis & Haemostasis     Hybrid Journal   (Followers: 105)
Thrombosis Research     Hybrid Journal   (Followers: 30)
Transplantation and Cellular Therapy     Hybrid Journal   (Followers: 11)
Veins and Lymphatics     Open Access   (Followers: 1)

           

Similar Journals
Similar Journals
HOME > Browse the 73 Subjects covered by JournalTOCs  
SubjectTotal Journals
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.213.60.33
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-